Clinical trials: Limping
Intermittent Claudication
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
The primary objective is to investigate in patients suffering from intermittent claudication due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by HMR1766 on top of clopidogrel may result in an…
- Trial name
- ACCELA (NCT00443287)
- Testing
- ataciguat (HMR1766), cilostazol
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 553 people
- Sponsor
- Sanofi